TLDR Omid Malekan says crypto treasury firms are driving recent Bitcoin price declines through aggressive selling. He explains that leveraged buys and debt-fueled expansion have made these firms vulnerable to market downturns. Malekan criticizes most crypto treasury companies for focusing on short-term profits instead of ecosystem growth. He warns that mass token releases and forced [...] The post Are Crypto Treasury Firms Secretly Fueling Bitcoin’s Steep Price Decline? appeared first on CoinCentral.TLDR Omid Malekan says crypto treasury firms are driving recent Bitcoin price declines through aggressive selling. He explains that leveraged buys and debt-fueled expansion have made these firms vulnerable to market downturns. Malekan criticizes most crypto treasury companies for focusing on short-term profits instead of ecosystem growth. He warns that mass token releases and forced [...] The post Are Crypto Treasury Firms Secretly Fueling Bitcoin’s Steep Price Decline? appeared first on CoinCentral.

Are Crypto Treasury Firms Secretly Fueling Bitcoin’s Steep Price Decline?

TLDR

  • Omid Malekan says crypto treasury firms are driving recent Bitcoin price declines through aggressive selling.
  • He explains that leveraged buys and debt-fueled expansion have made these firms vulnerable to market downturns.
  • Malekan criticizes most crypto treasury companies for focusing on short-term profits instead of ecosystem growth.
  • He warns that mass token releases and forced sales are creating heavy pressure on digital asset prices.
  • The professor calls this pattern the gangrene of crypto and urges more accountability in corporate treasury actions.

Omid Malekan, a blockchain author and adjunct professor at Columbia Business School, says crypto treasury companies are worsening market declines. He argues that their leveraged strategies and bulk token sales have created sharp drops in Bitcoin and other assets. The professor believes that these firms’ debt-driven expansion has intensified market instability.

Bitcoin Sales Linked to Treasury Exits

Malekan states that crypto treasury firms accumulated tokens using leveraged purchases and capital from share sales and convertible notes. He says these corporations often plan mass exits that lead to heavy token sales. These actions, he adds, frequently trigger market declines and erode investor confidence.

He notes that only a few crypto treasury companies focus on long-term value creation. Others, he claims, prioritize quick profits instead of ecosystem development. This behavior, he explains, continues to weaken trust across the digital asset market.

Malekan highlights that debt-funded acquisitions have worsened the issue. As debts rise, companies are forced to sell large holdings. These liquidations, he says, amplify downward pressure on asset prices.

Professor Warns Crypto Treasuries Fuel Market Decline

According to Malekan, many crypto treasury firms raised millions during new investor waves. They used this funding to purchase Bitcoin and other tokens in bulk. He explains that such aggressive buying made these firms vulnerable to falling asset values.

When debts grow or prices decline, they must sell to maintain solvency. Malekan warns that such sell-offs accelerate market drops. He calls these forced liquidations a recurring cause of price volatility.

Some crypto treasury firms also offer staking and liquidity services. These activities lock up tokens, which can increase market exposure. Malekan cautions that this practice deepens their vulnerability during rapid downturns.

Malekan describes the current situation as the “gangrene of crypto.” He argues that excessive funding and token issuance harm long-term stability. He says these companies issue tokens intended for lock-up but later release them during liquidity shortages.

He criticizes the lack of outcry from market participants.

Malekan believes such behavior drains confidence and reduces overall market capitalization.

He connects these corporate practices with broader economic pressures. Trade tensions between the United States and China, he notes, further influence market volatility. He stresses that both factors must be examined to understand current price trends.

Rising Numbers of Corporate Bitcoin Holders

Despite market turbulence, the number of crypto treasury companies continues to grow. Malekan cites recent data from Bitwise showing rapid corporate adoption. In October alone, 48 new firms added Bitcoin to their balance sheets.

The report says 207 companies now hold Bitcoin collectively exceeding one million BTC. Their combined reserves are valued at over $101 billion. Ethereum also remains popular, with 71 companies holding it as a core reserve asset.

In the past week, Bitcoin traded between $99,607.01 and $113,560. This range remains well below the October high of $126,000. Analysts continue to monitor how crypto treasury behavior affects these ongoing market trends.

The post Are Crypto Treasury Firms Secretly Fueling Bitcoin’s Steep Price Decline? appeared first on CoinCentral.

Market Opportunity
MASS Logo
MASS Price(MASS)
$0.0003896
$0.0003896$0.0003896
-2.30%
USD
MASS (MASS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26